Heart Disease News and Research

Latest Heart Disease News and Research

Rapid response teams in children's hospitals reduce risk of death, cardiac arrests

A children's hospital that added a rapid response medical team for patients not in the intensive care unit saw an 18 percent decrease in the death rate, and about a 70 percent decline in the rate of cardiac and respiratory arrests, according to a study in the November 21 issue of JAMA: The Journal of the American Medical Association.

21 Nov 2007

Pfizer wins day in court over Celebrex

Drug giant Pfizer has won a court ruling in the United States which could limit the lawsuits the company might possibly face over claims that its painkiller Celebrex caused heart attacks and strokes.

20 Nov 2007

World-famous heart transplant hospital given the all-clear

World-famous Papworth hospital in Cambridgeshire, England, has been given the all-clear to resume heart transplant surgery.

20 Nov 2007

Migraine sufferers found to have brain differences

According to new research from the U.S., migraine sufferers have structural differences in the part of the brain that deals with pain.

20 Nov 2007

Project aims to deepen the medical and research community's understanding of women's health

Women's bodies and medical needs are vastly different than men's way beyond their reproductive systems.

20 Nov 2007

Dyslexia expert Dr. Bruce McCandliss awarded Presidential honor

Dr. Bruce McCandliss, a psychologist at the Sackler Institute for Developmental Psychobiology and associate professor of psychology in psychiatry at Weill Cornell Medical College, has received a commendation by the President of the United States in the form of a Presidential Early Career Award for Scientists and Engineers (PECASE).

20 Nov 2007

Schering-Plough acquires Organon BioSciences

Schering-Plough Corporation has announced that it has completed the acquisition of Organon BioSciences N.V., creating a stronger combined company with broader human and animal health portfolios, an enhanced pipeline and increased R&D capabilities. Schering-Plough's agreement to acquire Organon BioSciences was announced on March 12, 2007.

20 Nov 2007

Wake-up call for young adults regarding heart health

Before you plop in front of the television for a day of football, pizza and beer, you might consider this: New research shows that in young adults, decades of hard-won progress in reducing the risk of heart disease appears to be stalling, as recent death rates from coronary disease remain almost unchanged in young men and may even be increasing in women.

20 Nov 2007

Study shows how men and women differ in their neural responses to psychological stress

According to a study that appears in the current issue of SCAN (Social Cognitive and Affective Neuroscience), researchers at the University of Pennsylvania School of Medicine discuss how men and women differ in their neural responses to psychological stress.

20 Nov 2007

New technique enables the detection of biomolecules' dynamic reactions in a single living cell

By taking advantage of the signature frequency by which organic and inorganic molecules absorb light, the team of researchers, led by Luke Lee, professor of bioengineering and director of UC Berkeley's Biomolecular Nanotechnology Center, can determine in real time whether specific enzymes are activated or particular genes are expressed, all with unprecedented resolution within a single living cell.

19 Nov 2007

Physical therapy in intensive care reduce hospital stays

The American Physical Therapy Association (APTA) cites the results of the first study to show the effectiveness of early physical therapy for patients in a medical intensive care unit (ICU).

19 Nov 2007

Nanogen reissued patent for diagnosis of chronic congestive heart failure

Nanogen, Inc. has announced that it has been granted U.S. Patent No. RE39,816, which is a reissue of United States Patent No. 6,461,828, titled, "Conjunctive Analysis of Biological Marker Expression For Predicting Cardiac Mortality".

19 Nov 2007

Sitting may increase risk of disease

Most people spend most of their day sitting with relatively idle muscles. Health professionals advise that at least 30 minutes of activity at least 5 days a week will counteract health concerns, such as cardiovascular disease, diabetes and obesity that may result from inactivity.

19 Nov 2007

Managing the chronic care of patients is not being captured in today's reimbursement system

Full-time physicians spend an average of one full day a week providing services for patients that are not reimbursed by Medicare, according to a new study conducted by Jeffrey Farber, MD, Assistant Professor of Geriatrics at The Mount Sinai Medical Center, and published the journal Annals of Internal Medicine.

19 Nov 2007

People with no risk factors for heart disease can still experience heart attacks

An Indiana University study found that after a countywide smoking ban was implemented, hospital admissions for such heart attacks dropped 70 percent for non-smokers -- but not for smokers.

19 Nov 2007

U.S. approval of Nexavar (sorafenib) for inoperable liver cancer

The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable.

19 Nov 2007

Drug-eluting stents versus bare-metal stents

Drug-eluting stents are just as safe and effective as traditional bare-metal stents when used in routine clinical practice, according to a new study by researchers at Rhode Island Hospital.

19 Nov 2007

New device for screening potential new drug compounds

A new device invented by researchers at the University of Virginia could save pharmaceutical companies significant time and money in screening potential new drug compounds.

19 Nov 2007

High cost of pain in Australia

For the first time, a dollar value has been attached to the high cost of pain in Australia in an MBF Foundation funded study that reveals a massive annual cost of $34.3 billion -- nearly $11,000 for each of the estimated 3.2 million people grappling with pain.

19 Nov 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007